Transitional CD38+IgM+ B cells are a key checkpoint in B-cell maturation. After leaving the bone marrow, these early B cells pass through defined stages—T1, T2, and T3—before becoming mature naïve B cells capable of participating in the adaptive immune response. Transitional B cells carry high levels of CD38 and IgM, markers that identify them as newly formed immune cells.
These cells play an important role in shaping the B-cell repertoire and ensuring immune tolerance. During maturation, transitional B cells undergo rigorous screening to eliminate autoreactive cells, reducing the risk of autoimmune disease. Because they are sensitive to disruptions in bone marrow function and peripheral immune regulation, transitional B-cell counts provide meaningful insight into immune system balance.
Clinically, elevated levels of transitional CD38+IgM+ B cells may indicate autoimmune activation (such as in systemic lupus erythematosus or rheumatoid arthritis), chronic inflammation, splenomegaly, or immune reconstitution after B-cell–depleting therapies. Low levels often point toward impaired B-cell development, including primary immunodeficiencies like CVID or X-linked agammaglobulinemia, bone marrow suppression, or medication effects.
Evaluating transitional B cells is useful when diagnosing suspected immune deficiencies, monitoring recovery after hematopoietic stem-cell transplantation, assessing response to immunotherapies, or tracking autoimmune disease activity.
Transitional CD38+IgM+ Abs
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.